Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343657 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL29259492 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL12600802 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15343918 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL30946520 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL24630164 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15279194 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL25426120 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL20495386 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL25426117 | 0.92 | NANP (0.36) | NANPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144849-B2 | Polishing composition and polishing method using the same | FUJIMI INCORPORATED (JP) | 2018-12-04 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9181281-B2 | Prodrugs of neuraminidase inhibitors | SineVir Therapeutics LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | SineVir Therapeutics LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20120264928-A1 | THERAPEUTIC PHARMACEUTICAL AGENT FOR DISEASES ASSOCIATED WITH DECREASE IN FUNCTION OF GNE PROTEIN, FOOD COMPOSITION, AND FOOD ADDITIVE | JAPAN HEALTH SCIENCES FOUNDATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | TSRL, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110160127-A1 | Prodrugs of Neuraminidase Inhibitors | TSRL, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100301014-A1 | Polishing Composition and Polishing Method Using the Same | FUJIMI INCORPORATED (JP) | 2010-12-02 | — | — | US | disclosed |
| EP-2237311-A1 | POLISHING COMPOSITION AND POLISHING METHOD USING THE SAME | FUJIMI INCORPORATED (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-4229441-A | Immunologic adjuvant | MERCK & CO., INC. (US) | 1980-10-21 | — | — | US | disclosed |
| EP-0012083-A1 | Immunologic adjuvant, process for preparation and vaccine containing such adjuvant | MERCK & CO. INC. (US) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | NANP 436/4885TDP1 3986/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | NANP 436/4885TDP1 3986/4885 |
| US-20110160127-A1 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | NANP 14/4885TDP1 1402/4885 |
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | NANP 14/4885TDP1 1402/4885 |
| US-20120264928-A1 | THERAPEUTIC PHARMACEUTICAL AGENT FOR DISEASES ASSOCIATED WITH DECREASE IN FUNCTION OF GNE PROTEIN, FOOD COMPOSITION, AND FOOD ADDITIVE | GNE, ENGASE, GNPDA1 | NANP 27/4885TDP1 4426/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | NANP 436/4885TDP1 3986/4885 |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | NANP 14/4885TDP1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.